



Supplemental Figure 5. Characterization of changes in immune infiltrate and tumor biology post-M032 treatment. A total of three matched pre- and post-M032 treatment samples (005, 008, and 009) were evaluated for CD3⁺ T cell, CD20⁺ B cell, IBA-1⁺ microglial/macrophage, FVIII-ra⁺ endothelial, and %Ki67⁺ tumor cells to determine if any significant changes were present after M032 treatment. No statistically significant differences were noted in this small sample size.